Physician profile

Steven E Kelley

Interventional Cardiology · Baton Rouge, LA

NPI 1922069103

$116,484.32

in general payments reported to CMS, 2019-2025

28 companies · $36K in 2025

The $36K reported for 2025 was more than what 95% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$79,375.00
Travel and Lodging$15,508.46
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$8,400.00
Food and Beverage$5,464.98

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Edwards Lifesciences Corporation $109,381.02 2019-2025 Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve
Abbott Laboratories $1,945.74 2019-2025 Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit
Medtronic, INC. $1,293.31 2021-2025 Symplicity G3, Corevalve Evolut R, Evera Mri Xt Dr Surescan
Shockwave Medical, INC $702.74 2022-2025 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Boston Scientific Corporation $614.79 2019-2025 General - Balloon Catheters, Bodyguardian
Novartis Pharmaceuticals Corporation $458.28 2019-2025
Abiomed $420.09 2023-2025 Impella
Merck Sharp & Dohme LLC $210.58 2021-2025 Verquvo
Amgen INC. $206.09 2019-2022
Angiodynamics, INC. $191.84 2024 Auryon Laser System 100-120 Vac
Irhythm Technologies, INC. $148.08 2022-2024 Zio Xt Patch, Zio Monitor
Janssen Pharmaceuticals, INC $131.75 2019-2023 Xarelto
Kestra Medical Technology Services, INC. $115.62 2023-2025 Assure Wcd
Alnylam Pharmaceuticals INC. $95.21 2024-2025 Onpattro
Astrazeneca Pharmaceuticals Lp $85.08 2021-2023 Farxiga
Show all 28 companies
CompanyGeneral paymentsYearsTop products
Pfizer INC. $66.81 2019-2024
E.R. Squibb & Sons, L.L.C. $52.97 2021-2025 Eliquis, Camzyos
Baxter Healthcare $48.55 2023 Hillrom - Carnation Ambulatory Monitor
Silk Road Medical, INC. $46.54 2024 Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent
Esperion Therapeutics, INC. $40.23 2021-2022
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $39.37 2023-2024 Lifevest
Itamar Medical INC $37.06 2025 Watchpatone
Cardiovascular Systems INC. $34.27 2022
Novo Nordisk INC $33.38 2024-2025 Wegovy
Impulse Dynamics (USA) INC. $28.30 2023 Optimizer
Cardiva Medical, INC. $23.28 2022
Kiniksa Pharmaceuticals International, Plc $18.04 2024 Arcalyst
Arbor Pharmaceuticals, INC. $15.30 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Steven E Kelley

$116,484.32

in general payments reported 2019-2025

Years
2019-2025
Top company
Edwards Lifesciences Corporation
Context
The $36K reported for 2025 was more than what 95% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).

https://glasscript.com/doctor/269120/steven-e-kelley

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.